Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern.
COVID-19
SARS-CoV-2
Zambia
spike mutations
variants of concern
whole-genome sequencing
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
received:
12
07
2022
revised:
15
08
2022
accepted:
19
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have significantly impacted the global epidemiology of the pandemic. From December 2020 to April 2022, we conducted genomic surveillance of SARS-CoV-2 in the Southern Province of Zambia, a region that shares international borders with Botswana, Namibia, and Zimbabwe and is a major tourist destination. Genetic analysis of 40 SARS-CoV-2 whole genomes revealed the circulation of Alpha (B.1.1.7), Beta (B.1.351), Delta (AY.116), and multiple Omicron subvariants with the BA.1 subvariant being predominant. Whereas Beta, Delta, and Omicron variants were associated with the second, third, and fourth pandemic waves, respectively, the Alpha variant was not associated with any wave in the country. Phylogenetic analysis showed evidence of local transmission and possible multiple introductions of SARS-CoV-2 VOCs in Zambia from different European and African countries. Across the 40 genomes analysed, a total of 292 mutations were observed, including 182 missense mutations, 66 synonymous mutations, 23 deletions, 9 insertions, 1 stop codon, and 11 mutations in the non-coding region. This study stresses the need for the continued monitoring of SARS-CoV-2 circulation in Zambia, particularly in strategically positioned regions such as the Southern Province which could be at increased risk of introduction of novel VOCs.
Identifiants
pubmed: 36146671
pii: v14091865
doi: 10.3390/v14091865
pmc: PMC9504048
pii:
doi:
Substances chimiques
Codon, Terminator
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35998978
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Rev Med Virol. 2022 Mar;32(2):e2271
pubmed: 34228851
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Cold Spring Harb Perspect Med. 2022 May 27;12(5):
pubmed: 35444005
Front Microbiol. 2022 Jan 14;12:827799
pubmed: 35095827
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Pathogens. 2021 Feb 09;10(2):
pubmed: 33572190
J Infect Dev Ctries. 2021 Dec 31;15(12):1782-1791
pubmed: 35044933
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
Nat Commun. 2014;5:3067
pubmed: 24473083
Viruses. 2021 May 17;13(5):
pubmed: 34067745
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Euro Surveill. 2021 Sep;26(39):
pubmed: 34596017
Int J Infect Dis. 2021 Jan;102:455-459
pubmed: 33035675
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
J Ovarian Res. 2021 May 21;14(1):70
pubmed: 34020688
J Adv Res. 2021 May;30:123-132
pubmed: 33262895
Nat Med. 2020 Jul;26(7):999-1003
pubmed: 32528154
J Med Virol. 2022 Apr;94(4):1738-1744
pubmed: 34905235
PeerJ. 2020 Jul 21;8:e9587
pubmed: 32742818
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
Clin Microbiol Infect. 2020 Jul;26(7):960-962
pubmed: 32234449
Front Immunol. 2020 Oct 07;11:576622
pubmed: 33117378
bioRxiv. 2020 Sep 04;:
pubmed: 32908977
BMC Infect Dis. 2022 Mar 16;22(1):261
pubmed: 35296265
China CDC Wkly. 2021 Jul 23;3(30):653-655
pubmed: 34594961
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Viruses. 2021 Oct 26;13(11):
pubmed: 34834967
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Emerg Infect Dis. 2020 Aug;26(8):
pubmed: 32396505
Lancet. 2021 Apr 3;397(10281):1265-1275
pubmed: 33773118
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):280-282
pubmed: 33630820
Heliyon. 2021 Aug;7(8):e07866
pubmed: 34458642
Int J Infect Dis. 2021 Mar;104:139-149
pubmed: 33359061
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
PLoS One. 2021 May 25;16(5):e0251368
pubmed: 34033650
J Virol. 2020 Jul 1;94(14):
pubmed: 32357959
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557
Science. 2021 Oct 22;374(6566):423-431
pubmed: 34672751
Front Cell Infect Microbiol. 2022 Jan 18;11:781429
pubmed: 35118007
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1547-1548
pubmed: 33090982
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Wellcome Open Res. 2021 Jul 28;6:192
pubmed: 35071798
J Med Virol. 2021 Oct;93(10):6016-6026
pubmed: 34241906
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Mol Biol Evol. 2017 Sep 1;34(9):2422-2424
pubmed: 28472384
Lancet Infect Dis. 2021 Aug;21(8):1070
pubmed: 34022142
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211024372
pubmed: 34211709
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W557-9
pubmed: 15980534
Nat Commun. 2016 Nov 22;7:13473
pubmed: 27874853
Vaccines (Basel). 2021 Mar 11;9(3):
pubmed: 33799505
BMJ. 2021 Feb 17;372:n334
pubmed: 33597166
J Clin Virol. 2020 Aug;129:104523
pubmed: 32623351
J Med Virol. 2020 Sep;92(9):1511-1517
pubmed: 32437052
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652